The WNBA and the manufacturer of the first-ever over-the-counter birth control pill, Perrigo, have announced a multi-year partnership. This partnership will kick off during the 2024 WNBA Draft and will focus on the league’s efforts to bring attention to civic engagement and reproductive health advocacy. The WNBA Chief Growth Officer, Colie Edison, emphasized the importance of expanding access to reproductive healthcare, a key issue that the league is dedicated to addressing. Opill, the first daily oral contraceptive available in the United States without a prescription, will serve as an associate partner of the WNBA Draft in New York.
Perrigo’s U.S. Women’s Health Brand Lead, Leila Bahbah, highlighted how Opill is changing the game in reproductive health, much like the WNBA has been a game-changer in sports and pop culture. The partnership aims to prioritize dialogue and resources in support of women’s reproductive health, building upon their shared commitment to foster equitable access and increase health education. This collaboration seeks to reach students on college campuses nationwide and educate others about accessible contraceptives. The WNBA’s values align with Perrigo’s, which makes the partnership authentic and meaningful.
The partnership with Perrigo is part of the WNBA’s ongoing efforts to address important issues that matter to players, such as reproductive healthcare. The league’s dedication to promoting health equity work and the players’ commitment to this cause make this collaboration significant. Opill’s availability without a prescription marks a milestone in reproductive health and the partnership with the WNBA amplifies the importance of accessible contraceptives. The WNBA Draft will now include Opill as an associate partner, further highlighting the significance of reproductive health advocacy in sports.
The partnership between the WNBA and Perrigo signifies a step forward in championing women’s reproductive health and advocating for equitable access to contraceptives. By aligning their values and goals, both organizations seek to empower women and promote health education. The collaboration’s focus on fostering dialogue and reaching students on college campuses aims to raise awareness and provide resources for reproductive health issues. This partnership underscores the WNBA’s commitment to addressing important societal issues and advocating for the well-being of their players and fans.
The WNBA and Perrigo’s partnership announcement coincides with the release of Opill, the first over-the-counter daily oral contraceptive in the United States. This partnership aims to highlight the importance of reproductive health advocacy and increase access to contraceptives. By integrating Opill into the WNBA Draft and implementing educational programs on college campuses, the partnership strives to make a meaningful impact in addressing women’s reproductive health issues. The collaboration underscores the shared commitment of both organizations to promoting health equity and providing resources for women’s well-being.
In summary, the WNBA’s partnership with Perrigo signifies a significant step towards advocating for women’s reproductive health and promoting access to contraceptives. This collaboration aligns with the league’s values and commitment to addressing important societal issues, such as health equity. Opill’s availability as an over-the-counter contraceptive marks a milestone in reproductive health, and integrating it into the WNBA Draft underscores the importance of promoting dialogue and education on reproductive health issues. This partnership aims to empower women, raise awareness, and provide resources for reproductive health advocacy, further solidifying the WNBA’s dedication to fostering positive societal change.
